AstraZeneca is all set to show quick development together with its global biologics research and development arm Med Immune. The company will show their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May-2 June 2015. At the meeting, 61 scientific abstracts will be presented and will support the development in immuno-oncology through advanced companion diagnostics and combination therapies.

According to Briggs Morrison, executive vice president, global medicines development and chief medical officer at AstraZeneca, “We are pleased to update on the breadth and depth of our oncology pipeline at ASCO. Our small molecule and biologic treatments target multiple areas of tumor biology across a diverse range of cancers, alone or in combination”.

Morrison added that the potential effect of their work in non-small cell lung cancer at different stages of the disease pathway is quite encouraging. He added that now the transformational potential of combination therapies is observed in immuno-oncology and these therapies are actually redefine cancer treatment.

He also said that the maturing data strengthen their reliance in this strategy, and, especially in MEDI4736 that showed durable activity across multiple tumor types and in different combinations.

Morrison added that the development could help those patients who are not benefited by standard of care or current monotherapies.

According to Bahija Jallal, executive vice president, MedImmune, their knowledge regarding potential of immuno-oncology is developing quickly and they have started unlocking its advantages for number of patients, but there is a lot to be done yet. Jallal also said that comprehensive, combination-focused development programme is focused on quickly increasing their scientific understanding, finding out all the important areas of the immune system that cancer can take over.